drugset / Trial / NCT01702649
Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects
Phase 1
Completed
36 enrolled
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
RandomizedParallel-groupDouble-blindTreatment
Summary
RPX2003 (biapenem) is being studied in combination with a beta-lactamase inhibitor to treat bacterial infections, including those due to multi-drug resistant bacteria.
Timeline
- Start
- 2012-08
- Primary completion
- 2012-11
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Biapenem | Small molecule | — | Intravenous |